Press Coverage

Questions Remain about Safety of Parkinson's Psychosis Drug: Report

One of the health highlights mentioned in this update compiled by editors outlines the conclusions from a recent ISMP QuarterWatch report that examined many unanswered questions about the safety and effectiveness of pimavanserin (Nuplazid), a drug used to treat psychosis in Parkinson's patients, and called for stronger warnings on its label.

For the full text, visit U.S. News & World Report online


More News

ECRI Institute and the Institute for Safe Medication Practices (ISMP) announce the successful completion of their plans to join forces. Effective today, ISMP is an ECRI Institute affiliate. By joining together, the two patient safety leaders have created one of the largest healthcare quality and